Summary:
In adults with diabetic foot ulcers (DFUs), sitagliptin (a DPP-4 inhibitor) significantly promoted the healing of DFUs compared to standard care without sitagliptin, though it was associated with minimal side effects related to gastrointestinal discomfort.
| PICO | Description |
|---|---|
| Population | Adults with diabetic foot ulcers (DFUs), a common complication of diabetes. |
| Intervention | Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, administered in addition to standard care. |
| Comparison | Standard care for diabetic foot ulcers without sitagliptin supplementation. |
| Outcome | Sitagliptin significantly improved DFU healing rates, potentially by enhancing CD34+ endothelial progenitor cell (EPC) mobilization in peripheral blood, independent of its glucose-lowering effects. Minimal gastrointestinal side effects were reported. |
Source: Gao, Wei, et al. “Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial.” Read article here.
